22:19 , Dec 17, 2018 |  BC Extra  |  Preclinical News

Downshifting CARs for better mileage

A study from Michel Sadelain's lab at the Memorial Sloan Kettering Cancer Center suggests that CARs with only one signaling domain are less prone to exhaustion and more equipped to form memory responses than CARs...
20:56 , Dec 14, 2018 |  BioCentury  |  Finance

Mission: Mainstream

Mission Bio Inc. plans to deploy its $30 million series B round to expand the applications and client base for its single-cell DNA analysis platform. Agilent Technologies Inc. (NYSE:A), Cota Capital, Laboratory Corp. of America...
03:31 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Germline editing gets technical

As the smoke clears from Jiankui He’s bombshell germline editing announcement, the gap between where the gene editing field is now and where it would need to be to support responsible germline editing has become...
13:08 , Dec 4, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; tissue markers Analysis of the copy numbers of mutant and wild-type alleles of oncogenes could help predict response to cancer therapies targeting those oncogenes. The method involves: performing genome-wide, allele-specific copy number...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
04:21 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
22:50 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma Cell and mouse studies suggest promoting PMAIP1 expression or inhibiting MCL1 could enhance the efficacy of BCL-2 inhibitors to treat diffuse large B cell lymphoma (DLBCL). In a DLBCL cell line,...
01:10 , Nov 10, 2018 |  BC Extra  |  Preclinical News

June highlights shorter CAR T culture times at SITC

In a presentation at the Society for Immunotherapy of Cancer (SITC) meeting Friday, CAR T cell pioneer Carl June highlighted preclinical data from University of Pennsylvania suggesting CAR T cell therapies could require as little...
03:10 , Nov 3, 2018 |  BioCentury  |  Politics, Policy & Law

Backing into value with Part B

The Trump Administration’s proposed revamp of Medicare Part B would cede value determinations to other countries by importing their cost-effectiveness standards on drug pricing. It could also lead to more experiments with alternative models for...
21:20 , Oct 29, 2018 |  BC Extra  |  Politics & Policy

Bach, Trusheim, Sen. Cassidy outline scheme for subscription-based purchasing

Peter Bach, Mark Trusheim and Sen. Bill Cassidy (R-La.) outlined a model for states to use as a basic reference point when implementing a subscription-based drug payment model for HCV drugs like the one proposed...